Rucaparib Approved for Ovarian Cancer.

  • Published 2017 in Cancer discovery

Abstract

The FDA approved the PARP inhibitor rucaparib to treat women with advanced ovarian cancer who have already been treated with at least two chemotherapies and have a BRCA1 or BRCA2 gene mutation identified by an approved companion diagnostic test. The agency also gave a nod to the FoundationFocus CDxBRCA test to detect BRCA alterations. 
DOI: 10.1158/2159-8290.CD-NB2016-164

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.